Related Experiment Video
Updated: Mar 19, 2026
08:28
Analysis of Congenital Heart Defects in Mouse Embryos Using Qualitative and Quantitative Histological Methods
Published on: March 10, 2020
7.4K
Abstract:
Two cohort studies, including more than 2500 pregnant women exposed to ondansetron in early pregnancy, have raised concerns over an increased risk of congenital heart defects.
Insights
Two cohort studies suggest ondansetron use in early pregnancy may increase the risk of congenital heart defects. Further research is needed to confirm these findings and guide clinical practice.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
- Pediatric Cardiology
Background:
- Ondansetron is commonly prescribed for nausea and vomiting during pregnancy.
- Existing data on ondansetron's safety in pregnancy have been limited.
- Congenital heart defects are a significant concern in prenatal health.
Purpose of the Study:
- To investigate the potential association between first-trimester ondansetron exposure and the risk of congenital heart defects.
- To analyze data from large-scale cohort studies to assess pregnancy outcomes.
Main Methods:
- Retrospective analysis of two large cohort studies.
- Inclusion of over 2500 pregnant women with early pregnancy exposure to ondansetron.
- Comparison of congenital heart defect rates between exposed and unexposed cohorts.
Main Results:
- Preliminary findings indicate a potential increased risk of congenital heart defects in infants born to mothers exposed to ondansetron during early pregnancy.
- Statistical significance and clinical implications require further evaluation.
Conclusions:
- The observed association warrants further investigation to establish causality.
- Pregnant individuals considering ondansetron should discuss potential risks and benefits with their healthcare providers.
- Continued monitoring of ondansetron's safety profile in pregnancy is recommended.
More Related Videos
Related Concept Videos
01:07Teratogenicity
4.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.4K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
778
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
778
01:21Intrauterine Drug Delivery Systems
106
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
106
01:29Drug Dosing: Infants and Children
698
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
698
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
1.0K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
1.0K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.6K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.6K